Before targeted therapies like trastuzumab, patients with HER2-positive lung cancer had limited options apart from standard chemotherapy, with generally poor outcomes and greater side effects.

HER2-positive metastatic breast cancer, an aggressive disease characterized by overexpression or amplification of HER2, occurs in approximately 15% to 20% of patients with metastatic breast cancer.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...